Retatrutide (LY3437943) vs Tirzepatide
Updated July 21, 2026 · Reviewed by the PeptidesDB Editorial team
A data-driven comparison of Retatrutide (LY3437943) and Tirzepatide (also searched as Tirzepatide vs Retatrutide (LY3437943)) — effect profiles, evidence, side effects, and which suits weight loss, muscle, or healing goals.
Verdict
Retatrutide (LY3437943) centers on metabolic, while Tirzepatide leans toward metabolic. On indexed research, Tirzepatide is ahead (Retatrutide (LY3437943): 0 studies, Preclinical; Tirzepatide: 2, Preclinical). Choose by goal — and read the primary studies. This is research information, not medical advice.
Key takeaways
- •Retatrutide (LY3437943) is strongest for metabolic; Tirzepatide for metabolic.
- •Evidence: Retatrutide (LY3437943) Preclinical (0 studies) vs Tirzepatide Preclinical (2).
- •Check the FDA-approval status chips above before assuming a legal use pathway.
Effect profiles, overlaid
At a glance
Triple GLP-1/GIP/Glucagon Agonist | Weight Loss & Diabetes
Dual GIP/GLP-1 Receptor Agonist | Weight Loss & Diabetes
Retatrutide (LY3437943) vs Tirzepatide: side-by-side
| Metric | Retatrutide (LY3437943) | Tirzepatide |
|---|---|---|
| Class | Weight Loss | Weight Loss |
| Regulatory status | Research use only | FDA-approved |
| Evidence grade | Preclinical | Preclinical |
| Studies indexed | 0 | 2 |
| Research level | Extensively Studied | FDA Approved |
| Strongest effect | Metabolic & appetite | Metabolic & appetite |
| Healing & recovery | 0.0 | 1.0▲ |
| Muscle & body comp | 0.0 | 0.0 |
| Metabolic & appetite | 5.0▲ | 5.0▲ |
| Neuro & mood | 0.0 | 0.0 |
| Sleep & circadian | 0.0 | 0.0 |
| Inflammation & immune | 0.0 | 1.0▲ |
| Skin & aesthetics | 0.0 | 3.0▲ |
▲ marks the higher community effect score (0–5 perceived-effect signal, not clinical efficacy).
Mechanism & pharmacokinetics
| Property | Retatrutide (LY3437943) | Tirzepatide |
|---|---|---|
| Mechanism | Triple GLP-1 / GIP / glucagon receptor agonist | Dual GIP + GLP-1 receptor agonist |
| Route | Subcutaneous injection | Subcutaneous injection |
| Half-life | ~6 days | ~5 days (≈120 h) |
| Time to peak | — | 8–72 h |
| Duration of action | Weekly dosing (investigational) | Weekly dosing |
Established pharmacology — curated for well-characterized compounds and AI-summarized otherwise. A blank (—) means no reliable single value is published (half-life figures for some peptides genuinely disagree across sources). Verify against primary sources such as FDA labels and ClinicalTrials.gov.
What is Retatrutide (LY3437943)?
Triple GLP-1/GIP/Glucagon Agonist | Weight Loss & Diabetes
Full Retatrutide (LY3437943) profile, mechanism & studies →What is Tirzepatide?
### Summary Tirzepatide is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist that has been investigated for its potential in managing type 2 diabetes and obesity. Its unique mechanism of action aims to enhance glycemic control and promote weight loss.
Full Tirzepatide profile, mechanism & studies →Which is better for your goal?
| Goal | Better fit | Why |
|---|---|---|
| Healing | Tirzepatide | 1.0/5 effect signal |
| Metabolic | Even | Both ~5.0/5 |
| Inflammation | Tirzepatide | 1.0/5 effect signal |
| Skin | Tirzepatide | 3.0/5 effect signal |
Fit reflects community-perceived effect profiles — not head-to-head trials. Read each peptide's studies before deciding.
Can you stack Retatrutide (LY3437943) and Tirzepatide?
People sometimes combine peptides that target different pathways, but there is little controlled research on this specific pairing and the interactions aren't well characterized. Because at least one is a research-use compound, we don't publish stacking or dosing protocols here. Any combination should be discussed with a qualified clinician.
Retatrutide (LY3437943) vs Tirzepatide: side effects
No community-reported effects logged yet.
No community-reported effects logged yet.
Anonymous community reports (count = number of reports), not clinical incidence rates.
What the research says
Retatrutide (LY3437943) has 0 approved studies indexed (Preclinical), and Tirzepatide has 2 (Preclinical). The Librarian re-checks PubMed, Europe PMC and ClinicalTrials daily, so these counts move. Open each profile to read the summaries and sources.
Frequently asked questions
Is Retatrutide (LY3437943) or Tirzepatide better?
It depends on your goal. Retatrutide (LY3437943) is strongest for metabolic; Tirzepatide for metabolic. Tirzepatide has more indexed studies (2). See the goal-by-goal breakdown above.
Is Retatrutide (LY3437943) or Tirzepatide better for weight loss?
They score similarly on the metabolic/appetite axis in the community data.
Which has more research, Retatrutide (LY3437943) or Tirzepatide?
Retatrutide (LY3437943) has 0 approved studies indexed (Preclinical); Tirzepatide has 2 (Preclinical). Higher counts mean more to read, not proven superiority.
Can you stack Retatrutide (LY3437943) and Tirzepatide?
Some users combine peptides, but there's little controlled data on this specific pairing, and interactions aren't well characterized. We don't publish stacking protocols for compounds that aren't FDA-approved. Discuss any combination with a qualified clinician.
What are the side effects of Retatrutide (LY3437943) vs Tirzepatide?
Retatrutide (LY3437943): no community-reported effects logged yet. Tirzepatide: none logged yet. These are anonymous reports, not incidence rates — see each profile.
Is Retatrutide (LY3437943) or Tirzepatide FDA-approved?
Retatrutide (LY3437943) is a research-use compound and is not FDA-approved. Tirzepatide is FDA-approved. Research-use status is not a legal clearance to compound or use in humans.
Is Tirzepatide better than Retatrutide (LY3437943)?
For metabolic, Tirzepatide has the edge; for metabolic, Retatrutide (LY3437943) does. Neither is universally "better" — it's goal-dependent, and both should be weighed against their evidence base above.
Comparing related peptides
Regulatory & legal status
Approval status varies (see the chips at the top). FDA approval and compounding rules for peptides change frequently, and research-use status is not a legal clearance for human use. The FDA does not review compounded drugs for safety, effectiveness, or quality. Verify current status with primary sources before acting. Last reviewed July 21, 2026.